TEL AVIV, Israel, Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd.
(NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company
focused on oncology and immunology, today hosts its investor
breakfast meeting at the Convene Conference Center near Grand
Central in New York, NY.
Philip Serlin, Chief Executive
Officer of BioLineRx, stated, "This annual event gives us the
opportunity to directly meet with our investors for updates on our
progress: steady advancements on our multiple clinical
programs in stem cell mobilization, combination immunotherapies and
acute myeloid leukemia (AML), as well as our new and novel
immuno-oncology therapy. And we are pleased to feature a
presentation by Dr. John DiPersio,
Chief, Division of Oncology at Washington
University School of Medicine, an internationally-renowned
hematologist and expert on the role of CXCR4 in stem-cell
mobilization and hematological malignancies. There remains a large,
unmet need for cancer therapies and we remain focused on advancing
programs that improve upon current treatments and the standard of
care."
In addition to the keynote presentation by Dr. DiPersio on bone
marrow transplantation and the role of CXCR4 in cancer, additional
topics for discussion at the ongoing BioLineRx investor breakfast
meeting include: (i) presentation on BL-8040 clinical development
plans in immuno-oncology combinations and AML, as well as on the
upcoming GENESIS Phase 3 study in stem cell mobilization for
autologous bone-marrow transplantation in multiple myeloma
patients; (ii) presentation of AGI-134, the Company's novel
immuno-oncology project; and (iii) an overview of the Company's
plans and expected milestones for 2018.
BioLineRx is hosting a live webcast of the investor breakfast
today between 9:00-10:30 am ET. To
access the webcast, please go to the breakfast event page on
BioLineRx's website. An audio replay of the meeting will also be
available for approximately three months following the meeting on
the breakfast event page.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase
2b study as an AML consolidation
treatment and is expected to initiate a Phase 3 study in stem cell
mobilization for autologous transplantation; and AGI-134, an
immunotherapy treatment in development for multiple solid tumors,
which is expected to initiate a first-in-man study in the first
half of 2018. In addition, BioLineRx has a strategic collaboration
with Novartis for the co-development of selected Israeli-sourced
novel drug candidates; a collaboration agreement with MSD
(tradename of Merck & Co., Inc.), on the basis of which the
Company has initiated a Phase 2a study in pancreatic cancer using
the combination of BL-8040 and MSD's KEYTRUDA; and a collaboration
agreement with Genentech, a member of the Roche Group, to
investigate the combination of BL-8040 and Genentech's atezolizumab
in several Phase 1b/2 studies for
multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the
Company's website at www.biolinerx.com, where you can review the
Company's SEC filings, press releases, announcements and events.
BioLineRx industry updates are also regularly updated on Facebook,
Twitter, and LinkedIn.
Various statements in this release concerning BioLineRx's
future expectations constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
more fully discussed in the "Risk Factors" section of BioLineRx's
most recent annual report on Form 20-F filed with the Securities
and Exchange Commission on March 23,
2017. In addition, any forward-looking statements represent
BioLineRx's views only as of the date of this release and should
not be relied upon as representing its views as of any subsequent
date. BioLineRx does not assume any obligation to update any
forward-looking statements unless required by law.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-646-863-6274
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
View original
content:http://www.prnewswire.com/news-releases/biolinerx-ltd-hosts-investor-breakfast-meeting-in-ny-300566737.html
SOURCE BioLineRx Ltd